MedTrace Logo

Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

NCT01390051 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-08-18

No results posted yet for this study

Summary

The purpose of the study is to investigate if treatment with an anticoagulant drug increases birth weight in pregnancies complicated by fetal growth restriction.

Conditions

  • Fetal Growth Retardation

Interventions

DRUG

Innohep (Tinzaparin)

Dose: 4,500 IU daily in half of the study populationrandomised to treatment

DRUG

tinzaparin

Dose 4,500 IE daily

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • LEO Pharma

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Anne-Mette Hvas, PhD, professor · Department of Clinical Biochemistry, Aarhus University Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01390051 on ClinicalTrials.gov